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Objectives. We studied the effects of clonidine on cardiac
sympathetic activity and left ventricular function in patients with
congestive heart failure (CHF).
Background. Sympathetic activation has major prognostic im-
plications in patients with heart failure. Clonidine, an imidazoline
and alpha2-receptor agonist, has been shown to cause a reduction
in generalized sympathetic activity.
Methods. Nine patients with CHF (left ventricular ejection
fraction 22 6 4% [mean 6 SEM]) received a 50 mg and 100 mg
bolus of clonidine intravenously. Study measurements included
right and left heart hemodynamics, cardiac output, rate of rise in
left ventricular peak positive pressure (LV 1dP/dt) and tau, along
with cardiac and total body norepinephrine spillover. The radio-
tracer method was used for calculation of norepinephrine spill-
over.
Results. Right and left heart filling pressures did not change in
response to either dose of clonidine. Mean arterial pressure fell
after the second dose of clonidine, from 94 6 8 to 82 6 6 mm Hg
(p < 0.05). The LV 1 dP/dt was reduced from 737 6 53 to 629 6
43 mm Hg/s (p < 0.05). Clonidine also caused a significant
increase in tau, as measured by the method of Weiss (65 6 3 vs.
74 6 4 ms, p < 0.01) and the direct pressure half-time technique
(48 6 2 vs. 54 6 3 ms, p < 0.01). Cardiac norepinephrine spillover
fell from 121 6 29 to 52 6 20 pmol/min in response to 100 mg of
clonidine (p < 0.01 vs. control).
Conclusions. Despite a significant fall in arterial pressure,
clonidine caused a marked reduction in sympathetic activity
directed at the heart. The negative inotropic and lusitropic effects
appear to be secondary to this reduction in sympathetic drive.
Because increased cardiac and generalized sympathetic activity
are strong predictors of an adverse outcome in patients with CHF,
the role of centrally active sympathoinhibitory agents in the
therapy of CHF deserves further exploration.
(J Am Coll Cardiol 1999;33:186–91)
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Sympathetic activation is a hallmark neurohormonal abnor-
mality in patients with congestive heart failure (CHF), which
has major prognostic implications (1,2). Importantly, this
increase in sympathetic outflow is not uniform, with the
greatest increase directed at the heart (3). In the setting of
CHF this increase in cardiac sympathetic activity has been
shown to be a strong predictor of clinical outcome (2). Some
adverse effects of increased sympathetic outflow directed at the
heart include desensitization and downregulation of cardiac
beta-adrenergic receptors (4), impairment of myocardial func-
tion and viability (5) and a predisposition to ventricular
arrhythmias (6).
Therapy of patients with CHF with beta-adrenergic recep-
tor blockade provides evidence that the inhibition of the effects
of sympathetic activation is beneficial in this disease (7,8).
Indeed, therapy with a beta-blocker is increasingly common as
part of the standard medical regimen of patients with CHF.
Importantly, beta-blockers, while inhibiting beta-adrenergic
receptors in the neuroeffector junction, may not reduce effer-
ent sympathetic outflow (9). Furthermore, they do not antag-
onize other compounds released at adrenergic nerve terminals,
such as dopamine and neuropeptide Y (10). Therefore, some
investigators have suggested that direct inhibition of central
sympathetic outflow might be an effective therapeutic ap-
proach in the therapy of heart failure (11,12).
Clonidine is a potent sympatholytic drug with central and
peripheral effects. Its mechanisms of action are not completely
understood, although it does involve stimulation of alpha2-
adrenergic and/or imidazoline receptors in the central nervous
system, causing inhibition of sympathetic outflow (13,14).
Clonidine also has peripheral effects, including both prejunc-
tional and postjunctional alpha2-adrenergic stimulation, al-
though there is considerable controversy regarding the relative
importance of these actions (15,16).
We hypothesized that clonidine would reduce sympathetic
activity directed at the heart in patients with CHF. Using the
radiotracer method of Esler et al. (3), we measured cardiac
and total body norepinephrine spillover in response to the
acute administration of clonidine in patients with heart failure.
To document the effects of sympathetic withdrawal on left
ventricular (LV) performance, direct measurements of LV
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pressure were obtained using a micromanometer-tipped cath-
eter.
Methods
Patient characteristics. Nine patients with CHF secondary
to dilated cardiomyopathy participated in the study. The
etiology of the LV dysfunction was ischemic in seven and
idiopathic in two patients. Eight patients were men (mean age
58 6 4 years). All patients were in New York Heart Associa-
tion functional class II and III and had an ejection fraction by
radionuclide angiography of #35% (mean 22 6 4%). Medical
therapy included angiotensin-converting enzyme inhibitors and
diuretic agents (n 5 9), digoxin (n 5 8), nitroglycerin (n 5 5)
and amiodarone (n 5 2). None of the patients were taking
beta-blockers. All medications were held on the morning of the
study. The protocol was approved by the Ethical Review
Committee for Human Experimentation of the University of
Toronto. Written informed consent was obtained from all
patients.
Hemodynamic and coronary flow measurements. A diag-
nostic right and left heart catheterization was performed,
without sedation. A pulmonary artery catheter was left in place
after the diagnostic procedure. A 7F coronary sinus thermodi-
lution flow catheter (type CCS-7U-90B, Webster Laboratories)
was inserted from an antecubital vein and positioned in the
coronary sinus for flow measurements and blood sampling. A
7F micromanometer-tipped catheter (Millar Industries) was
positioned in the LV for assessment of contractility (rate of
rise in LV peak positive pressure [1dP/dt]), relaxation (tau)
and LV end-diastolic pressure. The time constant of isovolu-
mic relaxation was determined in two different ways using
techniques previously described by our group (17). The first
method is a modification of that described by Weiss et al. (18),
such that tau (TL) is equal to 21/slope of the regression line
for the natural logarithm of LV pressure versus time for the
period from 2dP/dt to 5 mm Hg above LV end-diastolic
pressure. The second method is the direct measurement of the
pressure half-time (T1/2), as described by Mirsky (19). With
this method tau is measured directly, as the time required for
LV pressure to fall to one-half of its value at 2dP/dtmax. Left
ventricular pressure and the electrocardiogram (ECG) were
digitally recorded at 300 Hz using a Macintosh personal
computer equipped with a multichannel analogue to digital
converter. Data files were stored to disc for later analysis.
Using customized software developed in Labview (Version 3.0,
National Instruments Corporation, Austin, Texas), tau was
calculated off-line using identical methods to those described
earlier. Femoral artery pressure was monitored from an 8F
side-arm sheath (Cordis Laboratories). Cardiac output was
measured by the Fick method. The ECG, right atrial pressure,
pulmonary artery pressure, femoral artery pressure and LV
pressure and its first derivative (continuous electronic differ-
entiation) were recorded on a strip-chart recorder. For each
variable, the results were expressed as an average measure-
ment of 10 cardiac cycles in patients with sinus rhythm, and 15
cardiac cycles in patients with atrial fibrillation (n 5 2).
Coronary sinus blood flow measurements were performed in
duplicate at each measurement point according to the method
of Ganz et al. (20). All hemodynamic and blood flow analyses
were performed by a technician who had no knowledge of the
experimental condition.
Norepinephrine spillover measurements. Sympathetic ac-
tivity was estimated by the measurement of cardiac and total
body norepinephrine spillover (3). For these measurements,
tritiated norepinephrine (1 to 1.2-mCi/min with a 16-mCi
priming bolus of L-[2,5,6-3H] norepinephrine; New England
Nuclear) was infused into the femoral vein to steady-state
concentration in plasma. Norepinephrine clearance and spill-
over rates were calculated as follows (21):
Total body norepinephrine clearance ~liters/min!
5
@3H#NE infusion rate
Arterial plasma @3H#NE concentration
Total body norepinephrine spillover ~nmol/min!
5
@3H#NE infusion rate
Plasma NE specific activity
Cardiac norepinephrine spillover ~pmol/min!
5 @NEcs 2 NEart 1 ~NEext 3 NEart!# 3 CSPF
where [3H]NE indicates tritium-labeled norepinephrine;
NEext 5 transcardiac fractional extraction of tritium-labeled
norepinephrine; NEcs and NEart 5 coronary sinus and arterial
plasma norepinephrine concentrations, respectively; and
CSPF 5 coronary sinus plasma flow.
Analysis of plasma catecholamines. Catecholamine con-
centrations were measured with high performance liquid chro-
matography (HPLC) (9,22,23). Fractions from the HPLC
effluent containing tritium-labeled norepinephrine were as-
sayed by liquid scintillation spectroscopy. The detection limit
of the method was >0.1-hmol/liter, and the peak area was
linear from 0.1 to 50-hmol/liter. Intra-assay (n 5 8) and
interassay (n 5 14) coefficients of variation were 1.7% and
2.3%, respectively, for the determination of endogenous nor-
epinephrine. The biochemical analyses were performed by
personnel who had no knowledge of the experimental condi-
tions.
Abbreviations and Acronyms
CHF 5 congestive heart failure
1dP/dt 5 rate of rise in left ventricular peak positive
pressure
ECG 5 electrocardiogram
HPLC 5 high performance liquid chromatography
LV 5 left ventricular
TL 5 time constant of isovolumic relaxation
T1/2 5 pressure half-time
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Study protocol. After the diagnostic heart catheterization
and insertion of catheters for hemodynamic monitoring, the
patient was left undisturbed for a minimum of 20 min and
until tritium-labeled norepinephrine reached steady-state con-
centration in the plasma. Hemodynamic and coronary blood
flow measurements were then performed along with measures
of total body and cardiac norepinephrine spillover (control
measurements). Subsequently, patients were given a 50-mg
bolus of clonidine intravenously, and after 20 min, hemody-
namic, coronary blood flow and neurochemical measurements
were repeated. Patients were then given a second dose of
clonidine (100 mg bolus), and hemodynamic and catechol-
amine measurements were once again repeated after 20 min.
The purpose of the initial 50-mg dose was to ensure that the
drug was well tolerated and to examine the impact of the drug
on sympathetic activity in the absence of major changes in
systemic blood pressure. With the second 100-mg bolus, the
cumulative dose of clonidine administered was 150 mg. Be-
cause clonidine is nearly 100% bioavailable (24), we thought
that this dose was representative of the typical starting dose of
oral clonidine.
Statistical analysis. Comparisons of the effect of clonidine
on hemodynamic variables, catecholamine concentrations and
norepinephrine kinetics were made by one-way repeated mea-
sures analysis of variance. A Bonferroni correction was applied
for multiple comparisons. All data are presented as the mean
value 6 SEM.
Results
Baseline hemodynamic variables (Table 1). This study
enrolled nine patients with moderately severe CHF. Filling
pressures were elevated—mean right atrial pressure 10 6
1 mm Hg and LV end-diastolic pressure 22 6 2 mm Hg. The
cardiac index was depressed at 2.1 6 0.2 liters/min per m2.
Hemodynamic responses to clonidine (Table 1, Fig. 1). The
only hemodynamic variable that changed in response to 50 mg
of clonidine was femoral artery diastolic pressure, which
decreased from 73 6 6 to 66 6 6 mm Hg (p , 0.05 vs. control).
There was no change in heart rate, filling pressures, femoral
artery systolic pressure or cardiac index.
The second 100-mg dose of clonidine (150-mg cumulative
dose) caused a more significant hemodynamic response. Fem-
oral artery systolic pressure was reduced from 136 6 13 to
119 6 9 mm Hg and femoral artery diastolic pressure fell from
73 6 6 to 63 6 5 mm Hg (p , 0.05 vs. control, for both). Mean
pulmonary artery pressure was reduced from 29 6 2 to 26 6
2 mm Hg (p , 0.05 vs. control); however, no change in LV
end-diastolic pressure, right atrial pressure or cardiac index
was observed. There was a small but significant reduction in
heart rate (from 75 6 3 to 69 6 3 beats/min, p 5 0.05 vs.
control).
Effects of clonidine on left ventricle isovolumic perfor-
mance indexes (Table 1, Fig. 1). Intravenous clonidine was
associated with a negative inotropic and lusitropic response.
There was a highly significant decrease in 1dP/dt (from 737 6
53 to 629 6 43 mm Hg/s, control vs. clonidine 100 mg, p ,
0.05). Clonidine also caused a highly significant decrease in the
rate of LV isovolumic relaxation as measured by TL (from
65 6 3 to 74 6 4 ms, control vs. clonidine 100 mg, p , 0.01),
and by T1/2 (from 48 6 2 to 54 6 3 ms, control vs. clonidine
100 mg, p , 0.01).
Cardiac and generalized sympathetic responses (Table 2,
Fig. 2 and 3). Clonidine caused a dose-related reduction in
cardiac norepinephrine spillover. In response to the first dose
of clonidine (50 mg), cardiac spillover decreased from 121 6 29
Table 1. Hemodynamic Responses to Clonidine
Control
Clonidine
50 mg 100 mg
HR (beats/min) 75 6 3 75 6 3 69 6 3*
RA (mm Hg) 10 6 1 9 6 1 9 6 1
MPAP (mm Hg) 29 6 2 29 6 2 26 6 2*
LVEDP (mm Hg) 22 6 2 22 6 3 21 6 3
FAsyst (mm Hg) 136 6 13 131 6 12 119 6 9*
FAdiast (mm Hg) 73 6 6 66 6 6* 63 6 5*
FAmean (mm Hg) 94 6 8 88 6 7 82 6 6*
CI (liters/min per m2) 2.1 6 0.2 2.0 6 0.2 2.0 6 0.2
LV1dP/dt (mm Hg/s) 737 6 53 709 6 48 629 6 43*
TL (ms) 65 6 3 70 6 4* 74 6 4†
T1/2 (ms) 48 6 2 51 6 2* 54 6 3†
*p , 0.05 versus control. †p , 0.01 versus control. CI 5 cardiac index;
FAdiast 5 femoral artery diastolic pressure; FAmean 5 mean femoral artery
pressure; FAsyst 5 femoral artery systolic pressure; HR 5 heart rate; LVEDP 5
left ventricular end-diastolic pressure; LV1dP/dt 5 rate of rise in left ventricular
peak positive pressure; MPAP 5 mean pulmonary artery pressure; T1/2 5
pressure half-time; TL 5 time constant of isovolumic relaxation (tau).
Figure 1. Hemodynamic responses to 50 and 100 mg of clonidine.
FAmean 5 mean femoral artery pressure; LVEDP 5 left ventricular
end-diastolic pressure; LV1dP/dt 5 rate of rise in left ventricular peak
positive pressure; TL 5 rate of isovolumic relaxation measured by the
method of Weiss (18). *p , 0.05 versus control. †p , 0.01 versus
control. Data are expressed as the mean value 6 SEM.
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to 79 6 26 pmol/min (p , 0.05 vs. control). The second dose
of clonidine (100 mg) caused an additional fall in cardiac
spillover to 52 6 20 pmol/min (p , 0.01 vs. control).
Similar to the change in cardiac norepinephrine spillover,
there was a significant decrease in the plasma norepinephrine
concentration gradient measured across the heart (coronary
sinus concentration minus arterial concentration). The first
dose of clonidine caused a reduction in the transcardiac
norepinephrine gradient (p 5 NS). With the second dose the
transcardiac gradient decreased from 1.0 6 0.3 to 0.4 6 0.2
pmol/ml (control vs. clonidine 100 mg, p , 0.05).
The first dose of clonidine caused a significant reduction in
total body norepinephrine spillover from 2.98 6 0.66 to
2.32 6 0.56 nmol/min (p , 0.05 vs. control). There was an
additional reduction to 1.45 6 0.36 nmol/min (p , 0.01 vs.
control) in response to the second dose of clonidine. There
was no significant change in total body clearance of norepi-
nephrine.
Discussion
To our knowledge, this is the first report to examine the
effects of clonidine on cardiac sympathetic activity in humans.
We have demonstrated that clonidine has potent inhibitory
effects on cardiac-specific sympathetic outflow. After a total
intravenous dose of 150 mg of clonidine, there was a 59 6 9%
reduction in cardiac norepinephrine spillover. This cardiac
sympathoinhibitory effect was much larger than that observed
with other agents used in the treatment of CHF, including
digoxin and beta-adrenergic blockers (9,22). The results of the
present study are consistent with those reported by Lang et al.
(12), who found that clonidine significantly reduced total body
norepinephrine spillover in patients with heart failure. Simi-
larly, they are consistent with observations that clonidine
reduces plasma norepinephrine in patients with heart failure
(25,26). Importantly, the decrease in cardiac sympathetic ac-
tivity that we have documented could not have been inferred
from the systemic inhibitory responses, because we (23) and
other investigators (21) have shown that cardiac sympathetic
responses can be divergent from those observed in the periph-
ery.
A unique feature of this investigation was the simultaneous
measurement of cardiac sympathetic activity and LV isovolu-
mic performance. This allowed us to evaluate the effect of
sympathetic withdrawal on 1dP/dt and tau in patients with
CHF. Although previous investigations have demonstrated
negative inotropic and lusitropic responses during acute beta-
adrenergic receptor blockade (27), these responses may have
been modified by a reflex increase in central sympathetic
outflow (9).
Inotropic effects. The administration of clonidine was as-
sociated with important decreases in 1dP/dt, a finding which
we believe documents the dependency of ventricular contrac-
tility on sympathetic outflow in the setting of heart failure.
Clonidine did cause a significant reduction in systemic arterial
blood pressure, a hemodynamic effect that may also have
caused a reduction in 1dP/dt (28). Importantly, work from our
laboratory (23) and that of others (29) has shown that similar
reductions in arterial pressure had no effect on 1dP/dt in the
setting of heart failure. Although this suggests that clonidine
had negative inotropic effects, it is possible that the decrease in
Figure 2. Cardiac norepinephrine spillover (CANESP) and total body
norepinephrine spillover (TBNESP) at control values and in response
to 50 and 100 mg of clonidine. *p , 0.05 versus control. †p , 0.01
versus control. Data are expressed as the mean value 6 SEM.
Table 2. Neurochemical and Flow Responses to Clonidine
Control
Clonidine
50 mg 100 mg
NEart (pmol/ml) 1.5 6 0.3 1.2 6 0.3 0.8 6 0.2*
NEcs (pmol/ml) 2.5 6 0.5 1.9 6 0.5* 1.3 6 0.4*
CANESP (pmol/min) 121 6 29 79 6 26* 52 6 20†
NEext (%) 66 6 4 69 6 4 69 6 3
CSBF (ml/min) 143 6 35 118 6 21 109 6 19
TBNECL (liters/min) 2.11 6 0.17 2.04 6 0.18 1.82 6 0.17
TBNESP (nmol/min) 2.98 6 0.66 2.32 6 0.56* 1.45 6 0.36†
*p , 0.05 versus control. †p , 0.01 versus control. CANESP 5 cardiac
norepinephrine spillover; CSBF 5 coronary sinus blood flow; NEart 5 arterial
plasma norepinephrine; NEcs 5 coronary sinus plasma norepinephrine; NEext 5
cardiac extraction of norepinephrine; TBNECL 5 total body norepinephrine
clearance; TBNESP 5 total body norepinephrine spillover.
Figure 3. Arterial (open bars) and coronary sinus (solid bars) plasma
norepinephrine at control values and in response to 50 and 100 mg of
clonidine. There is a significant reduction in the transcardiac gradient
of plasma norepinephrine in response to 100 mg of clonidine. This
results from a significantly greater decrease in the coronary sinus
plasma norepinephrine level as compared with the arterial plasma
norepinephrine level. *p , 0.05 versus control. †p , 0.01 versus
control. ‡p , 0.05 for comparison between the norepinephrine trans-
cardiac gradient (coronary sinus 2 arterial) with 100 mg of clonidine
and control level. Data are expressed as the mean value 6 SEM.
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heart rate and afterload, along with potential changes in
preload, may have contributed to some, or all, of the observed
reduction in 1dP/dt.
Lusitropic effects. Clonidine was also associated with a
negative lusitropic effect. This occurred despite a significant
fall in systemic arterial pressure, a hemodynamic effect that
would have been expected to cause an acceleration in the rate
of isovolumic relaxation (30), particularly in patients with heart
failure (31). Tau has been shown to be sensitive to changes in
heart rate, however, this only occurred in the setting of large
changes, in the range of 20–40 bpm (32). Further, with the
50-mg dose of clonidine, there was a significant prolongation in
tau in the absence of a change in heart rate. Therefore, we
believe that the 50 mg dose of clonidine had a direct negative
lusitropic effect. With the 100 mg dose, there was a further
increase in tau. After this dose, however, there was a significant
decrease in heart rate, an effect that may have made some
contribution to the observed increase in tau.
Sympathoinhibitory effects. The results of this investiga-
tion have potential clinical relevance to the use of sympatho-
lytic agents in CHF. First, we have demonstrated that the
potent sympathoinhibitory effects of clonidine were well toler-
ated. The decrease in blood pressure was moderate, and no
patient was symptomatic as a result. Despite the significant fall
in 1dP/dt and increase in tau, LV filling pressure did not rise
and the cardiac index was maintained. We believe that this
tolerability of clonidine is mainly a result of the reduction in
afterload caused by the drug. It is important to recognize that
the sympathoinhibitory effect of clonidine was observed de-
spite a significant fall in arterial blood pressure, a hemody-
namic response that is classically associated with a reflex
increase in sympathetic outflow, both in patients with normal
ventricular function and in those with heart failure (23).
Second, important sympathoinhibition was obtained with small
doses of intravenous clonidine. Because clonidine is nearly
100% bioavailable (24), oral doses of 50 to 100 mg should also
be associated with significant inhibitory effects on sympathetic
outflow. Such doses of clonidine would likely be associated
with a lower incidence of side effects than that observed with
traditional antihypertensive regimens in which 200 to 600 mg
are administered twice daily (24). Finally, although it has been
recognized for many years that sympathetic activation in
chronic heart failure is a marker for adverse outcome (1), the
hypothesis that a central sympathoinhibitory agent would have
beneficial effects on clinical outcome in patients with chronic
heart failure has yet to be tested. The tolerability of clonidine,
as well as the low dose required to reduce cardiac sympathetic
outflow, suggests the feasibility of these agents for potential
large-scale clinical trials. It should be noted that the potential
role of drugs like clonidine in the therapy of heart failure has
been recognized for many years. Indeed, Giles et al. (11)
suggested this approach for the treatment of heart failure more
than 15 years ago.
Study limitations. We do not believe that the sympathoin-
hibitory responses represent the effect of time, because previ-
ous studies from our laboratory have demonstrated that both
hemodynamic and neurochemical variables remain stable dur-
ing periods similar to those involved in the present study
(22,23). In a recent study involving patients with severe heart
failure, we made hemodynamic and neurochemical measure-
ments at baseline and after a 30-min control period. Hemody-
namic variables as well as measures of total body and cardiac
norepinephrine spillover remained unchanged during this pe-
riod (22). In another study examining the same variables in
patients with heart failure, we demonstrated that control and
recontrol measurements made 40 to 50 min apart were not
different (23). Therefore, in patients with chronic heart failure,
hemodynamic variables and measures of sympathetic activity
are stable and reproducible over an observation period similar
to that used in the present report. Therefore, we conclude that
the hemodynamic and neurochemical changes observed are
secondary to the administration of clonidine and are not an
effect of time. Finally, these patients were taking a number of
medications that may have had inhibitory effects on both
cardiac and systemic sympathetic activity. This may have
reduced baseline levels of sympathetic activity, which in turn,
may have modified sympathetic responses to clonidine. Never-
theless, clonidine still had potent sympathoinhibitory effects,
even in this group with treated CHF.
Clinical implications. This report is the first to examine the
effects of a direct sympathoinhibitory drug on cardiac sympa-
thetic activity in human heart failure. The results demonstrate
that the acute administration of clonidine has potent inhibitory
effects on cardiac sympathetic activity in patients with stable
functional class II or III CHF, and that this effect is well
tolerated. Whether the drug would have similar effects and be
well tolerated in patients with more severe disease is a question
which our study cannot address. Nevertheless, observations
made in this study should lead to further investigations exam-
ining the effects of long-term therapy with clonidine or other
centrally active sympathoinhibitory compounds on both mea-
sures of sympathetic activity and clinical outcome. Because
increases in central sympathetic outflow appear to have ad-
verse effects in patients with heart failure (2), the use of central
sympathoinhibitory agents in the therapy of this condition has
strong appeal. In contrast, it is important to remember that a
reduction in central sympathetic outflow, in the absence of
adrenergic receptor blockade, may be inadequate to protect
the heart from the adverse effects of increased adrenergic
drive. Therefore, the efficacy of central sympathoinhibition will
have to be compared with the effects of adrenergic receptor
blockade. Indeed, it is possible that the most effective ap-
proach would be a regimen that included both central sympa-
thoinhibition and peripheral adrenergic receptor blockade.
The observation made in this study should lead to further
investigations examining the effects of long-term therapy with
clonidine or other centrally active sympathoinhibitory com-
pounds on both measures of sympathetic activity and clinical
outcome.
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